Discovery of Carbonic Anhydrase 9 as a Novel CLEC2 Ligand
Author Information
Author(s): Hoffmann Sebastian, Berger Benedict-Tilman, Lucas Liane Rosalie, Schiele Felix, Park John Edward
Primary Institution: Boehringer Ingelheim Pharma GmbH & Co. KG
Hypothesis
Can carbonic anhydrase 9 (CA9) interact with CLEC2 and influence immune cell signaling?
Conclusion
The study identified CA9 as a novel ligand for CLEC2, revealing its potential role in immune cell interactions and cancer therapy.
Supporting Evidence
- CA9 was found to bind to platelets and activate CLEC2 signaling.
- The interaction between CA9 and CLEC2 was mediated via a specific amino acid sequence.
- CA9's role in cancer makes it a promising target for therapeutic strategies.
Takeaway
Researchers found that a protein called CA9 can stick to another protein called CLEC2, which might help in treating cancer.
Methodology
The study used a recombinant protein library and flow cytometry to screen for interactions between membrane proteins and immune cells.
Potential Biases
The results may be biased towards the dominant CD14high population in blood samples.
Limitations
The study may have missed some interactions due to the focus on a dominant cell population and potential indirect binding effects.
Participant Demographics
The study involved blood samples from healthy volunteers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website